weight loss drug news today glp-1 New oral delivers up to 12% in 36 weeks 🚨 GLP-1 WEIGHT LOSS DRUGS:

Some GLP-1 medications have demonstrated cardiovascular protective effects in specific populationsliraglutide, semaglutide injection, and dulaglutide have shown cardiovascular outcome benefits, with Wegovy (semaglutide) recently receiving an FDA indication for cardiovascular risk reduction in adults with established cardiovascular disease and either overweight or obesity

Current Research on Ozempic and Fibromyalgia Treatment Direct clinical trials examining Ozempic specifically for fibromyalgia are limited, but emerging case reports and observational data suggest symptom improvement in some patients

Anderson SL, Trujillo JM

Kobilka B

Cell Metab 34, 12341247 e1239 (2022)